News

• The PCCTC Selects Tempus as Sequencing and Analytics Provider for...

  Press Releases by Tempus August 17, 2017

  

  Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volume...

  Learn More

• Dr. Howard I. Scher on the Definition of Castration-Sensitive/Nai...

  Press Releases by UroToday August 7, 2017

  

  The PCCTC's Scientific Oversight Committee chair speaks with UroToday at the 2017 Advanced Prostate Cancer Consensus Con...

  Learn More

• PCCTC Trial Establishes Safety, Antitumor Activity of Apalutamide...

  Press Releases by admin July 25, 2017

  

  Study represents a new standard that demonstrates the patient experience, useful for physicians when considering options...

  Learn More

• Dr. Lorelei Mucci Discusses Innovative IRONMAN Registry

  Press Releases by admin July 6, 2017

  

  IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer...

  Learn More

• Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivi...

  Press Releases by Bryant Furlow June 8, 2017

  

  PCCTC study serves as the foundation for a therapeutically relevant classification of prostate cancer...

  Learn More

• PCCTC Trial Results: Neoadjuvant Enzalutamide Prior to Prostatect...

  Press Releases by admin May 9, 2017

  

  Study led by the University of Washington published in Clinical Cancer Research provides evidence of continued androgen ...

  Learn More